Cytochrome P450 2C19 (CYP2C19) Genotyping
Cytochrome P450 (CYP450) enzymes are responsible for the metabolism of a wide range of endogenous compounds and commonly prescribed medications. These enzymes are primarily expressed in the liver and exhibit significant interindividual variability due to genetic polymorphisms. Variations in CYP450 enzyme activity can result in reduced, absent, or increased drug metabolism, which may lead to therapeutic failure or adverse drug reactions.
CYP2C19 is a highly polymorphic enzyme that plays a critical role in the metabolism of multiple clinically important medications, including antiplatelet agents, proton pump inhibitors, antidepressants, and certain antiepileptic drugs. Genetic variants in the CYP2C19 gene influence enzyme activity and are used to classify individuals into predicted metabolizer phenotypes: poor metabolizer (PM), intermediate metabolizer (IM), normal metabolizer (NM), rapid metabolizer (RM), and ultrarapid metabolizer (UM).
The most clinically relevant alleles include loss-of-function variants such as *2 and *3, which reduce or eliminate enzyme activity, and the gain-of-function variant *17, which is associated with increased enzyme activity. The combination of alleles inherited by an individual determines the overall metabolic phenotype and influences drug response. For example, CYP2C19 is required for activation of clopidogrel, and reduced-function alleles are associated with decreased antiplatelet effect and increased risk of adverse cardiovascular outcomes.
CYP2C19 genotyping provides clinically actionable information that can guide drug selection and dosing to improve efficacy and reduce toxicity. Clinical guidelines, including those from the Clinical Pharmacogenetics Implementation Consortium (CPIC), support genotype-guided therapy for several medications metabolized by CYP2C19.
- Guidance of antiplatelet therapy, particularly clopidogrel, to reduce risk of therapeutic failure or adverse cardiovascular events
- Optimization of antidepressants and psychotropic medication therapy, including selective serotonin reuptake inhibitors and tricyclic antidepressants
- Adjustment of proton pump inhibitor therapy based on metabolism rate to improve treatment response.
- Support of individualized drug selection and dosing for medications metabolized by CYP2C19
Results are reported as predicted metabolizer phenotypes based on genotype, including poor, intermediate, normal, rapid, and ultrarapid metabolizers.
- Poor metabolizers have little to no functional CYP2C19 activity due to two loss-of-function alleles and are at increased risk of drug accumulation and toxicity for medications inactivated by CYP2C19. For prodrugs such as clopidogrel, poor metabolizers may have reduced therapeutic effect and should be considered for alternative therapy.
- Intermediate metabolizers have reduced enzyme activity and may exhibit altered drug response depending on the medication and clinical context.
- Normal metabolizers have expected enzyme activity and typically respond to standard dosing.
- Rapid and ultrarapid metabolizers have increased enzyme activity due to one or two gain-of-function alleles and may experience reduced drug exposure and potential treatment failure for medications inactivated by CYP2C19.
- Clinical interpretation should consider additional factors including concomitant medications, drug interactions, comorbid conditions, and patient-specific variables.
The following is a list of major therapeutic classes with drugs that are substantially metabolized by CYP2C19
PPIs: lansoprazole, omeprazole, pantoprazole, rabeprazole
Anti-epileptics: diazepam, phenytoin, S-mephenytoin, phenobarbitone, amitriptyline, carisoprodol, citalopram, chloramphenicol, clomipramine, clopidogrel, cyclophosphamide, hexobarbital, imipramine N-DeME, indomethacin, R-mephobarbital, moclobemide, nelfinavir, nilutamide, primidone, progesterone, proguanil, propranolol, teniposide, R-warfarin
diazepam, phenytoin, S-mephenytoin, phenobarbitone, amitriptyline, carisoprodol, citalopram, chloramphenicol, clomipramine, clopidogrel, cyclophosphamide, hexobarbital, imipramine N-DeME, indomethacin, R-mephobarbital, moclobemide, nelfinavir, nilutamide, primidone, progesterone, proguanil, propranolol, teniposide, R-warfarin
The following is a list of major inhibitors that compete with other drugs for a particular enzyme thus affecting the optimal level of metabolism of the substrate drug which in many cases affect the individual's response to that particular medication, e.g. making it ineffective.
Most common inhibitors are: lansoprazole, omeprazole, pantoprazole, rabeprazole, chloramphenicol, cimetidine, felbamate, fluoxetine, fluvoxamine, indomethacin, ketoconazole, modafinil, oxcarbazepine, probenicid, ticlopidine, topiramate.
CYP2C19 \*1/\*1 (Normal metabolizer)
Specimen collection can be done through collection of buccal (inner cheek) cells, gathered by rubbing a buccal swab (similar to a Q-tip and generally 4 swabs) on the inner cheek. Blood can also be collected through venipuncture to acquire a minimum of 5-10 cc of whole blood in a lavender top (EDTA) tube.
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14days
- Frozen: 30 days
3-7 days.
- Arch Pharm Res. 2011 Nov;34(11):1799-816. [PMID: 22139682]
- Circulation. 2010; 121(4):512-8.PMID: 20083681
- N Engl J Med. 2009; 360(4):363-75.PMID: 19106083
- Pharmacogenomics. 2009 Nov;10(11):1799-817. [PMID: 19891556]